Abstract:Tau phosphorylation at specific Alzheimer's disease (AD)‐relevant epitopes negatively affects mitochondria, with the extent of dysfunction and stress response varying according to the sites of phosphorylation. ATP levels were reduced in cells expressing either tau pseudophosphorylated at S396/404 (2EC) or T231/S235 (2EM), and ROS production increased in 2EC cells during oxidation of succinate compared to wild type (T4)‐expressing cells. Thapsigargin reduced mitochondrial membrane potential (Ψm) and increased ROS production in both 2EC and 2EM cells. Altogether, these findings extend our understanding of potential mechanisms whereby phosphorylated tau promotes mitochondria dysfunction in tauopathies, including AD. The thickness of the green arrows corresponds with the magnitude of effect. The longer red and black arrows represent experiments conducted with stressors and in the basal state, respectively. Phosphorylation of tau at sites associated with Alzheimer's disease (AD) likely plays a role in the disease progression. Mitochondrial impairment, correlating with increased presence of phosphorylated tau, has been identified as a contributing factor to neurodegenerative processes in AD. However, how tau phosphorylated at specific sites impacts mitochondrial function has not been fully defined. We examined how AD‐relevant phosphomimetics of tau impact selected aspects of mitochondrial biology. To mimic phosphorylation at AD‐associated sites, the serine/threonine (Ser/Thr) sites in wild‐type green fluorescent protein (GFP)‐tagged tau (T4) were converted to glutamic acid (E) to make pseudo‐phosphorylated GFP‐tagged Ser‐396/404 (2EC) and GFP‐tagged Thr‐231/Ser‐235 (2EM) constructs. These constructs were expressed in immortalized mouse hippocampal neuronal cell lines, and their impact on specific mitochondrial functions and responses to stressors were measured. Phosphomimetic tau altered mitochondrial distribution. Specifically, mitochondria accumulated in the soma of cells expressing either 2EC or 2EM and neurite‐like extensions in 2EC cells were shorter. Additionally, adenosine triphosphate levels were reduced in both 2EC‐ and 2EM‐expressing cells, and reactive oxygen species (ROS) production increased in 2EC cells during oxidation of succinate when compared to T4‐expressing cells. Thapsigargin reduced mitochondrial membrane potential and increased ROS production in both 2EC and 2EM cells relative to T4 cells, with no significant difference in the effects of rotenone. These results show that tau phosphorylation at specific AD‐relevant epitopes negatively affects mitochondria, with the extent of dysfunction and stress response varying according to the sites of phosphorylation. Altogether, these findings show that phosphorylated tau increases mitochondrial susceptibility to stressors and extend our understanding of potential mechanisms whereby phosphorylated tau promotes mitochondria dysfunction in tauopathies, including AD.

Microtubule‐affinity regulating kinase family members distinctively affect tau phosphorylation and promote its toxicity in a Drosophila model

Microtubule affinity-regulating kinase 4 with an Alzheimer's disease-related mutation promotes tau accumulation and exacerbates neurodegeneration

Cdk5 increases MARK4 activity and augments pathological tau accumulation and toxicity through tau phosphorylation at Ser262.

Reduction of Protein Kinase MARK4 in the Brains of Experimental Scrapie Rodents and Human Prion Disease Correlates with Deposits of PrP(Sc).

Modification of the Drosophila model of in vivo Tau toxicity reveals protective phosphorylation by GSK3β

Disulfide bond formation in microtubule-associated tau protein promotes tau accumulation and toxicity in vivo

Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP

Aggregation promoting sequences rather than phosphorylation are essential for Tau-mediated toxicity in

Role of Microtubule-Associated Protein Tau Phosphorylation in Alzheimer’s Disease

Ischemic axonal injury up-regulates MARK4 in cortical neurons and primes tau phosphorylation and aggregation

Inhibition of MARK4 by serotonin as an attractive therapeutic approach to combat Alzheimer's disease and neuroinflammation

Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation

An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry

Site‐specific phosphorylation of tau impacts mitochondrial function and response to stressors

Microtubule affinity-regulating kinase 4: structure, function, and regulation

Global Analysis of Phosphorylation of Tau by the Checkpoint Kinases Chk1 and Chk2 in Vitro.

Effects of Tau on Aβ-induced Synaptic Damage in a Drosophila Model of Alzheimer's Disease.

Identification of a Reciprocal Negative Feedback Loop Between Tau-Modifying Proteins MARK2 Kinase and CBP Acetyltransferase.

Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases

The C-terminus of Tau Protein Plays an Important Role in Its Stability and Toxicity.

Phosphorylation at serine 214 correlates with tau seeding activity in an age-dependent manner in two mouse models for tauopathies and is required for tau transsynaptic propagation.